Establishment Labs Holdings Inc (VGG312491084)
XSTU 
Summary
VGG312491084 Chart
Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.7 per share a year ago.
Establishment Labs Insider Sells 37,500 Shares as Stock Jumps 128% in a Year
37,500 shares were sold indirectly for a total transaction value of approximately $2.45 million on April 14, 2026. All shares sold were indirectly held via Sariel Group Ltd, with no direct shares sold; after the trade, the insider retains 45,193 direct shares and 1,182,504 indirect shares, per the Form 4.
Establishment Labs Holdings Inc (VGG312491084) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Establishment Labs Holdings Inc ever had a stock split?
Establishment Labs Holdings Inc Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Fillipo Peter Caldini CEO | XSTU Exchange | VGG312491084 ISIN |
| CR Country | 1,034 Employees | - Last Dividend | - Last Split | 19 Jul 2018 IPO Date |
Overview
Establishment Labs Holdings Inc. is a prominent medical technology company that has carved a niche for itself in the realm of aesthetic and reconstructive plastic surgery. Having been incorporated in 2004, the company is headquartered in Alajuela, Costa Rica. Over the years, Establishment Labs has dedicated itself to the manufacture and marketing of high-quality medical devices, focusing predominantly on innovations within the breast implant sector. Its products, underpinned by advanced technology, are designed to cater to the diverse needs of patients worldwide, aiming to enhance both aesthetic appeal and comfort. The company leverages a robust network of distributors and direct sales forces to deliver its solutions to physicians, hospitals, and clinics across key regions including Europe, the Middle East, Latin America, and Asia, thereby securing a significant position in the global medical aesthetic market.
Products and Services
- Motiva Implants
- Motiva Ergonomix and Motiva Ergonomix2
- Motiva Flora Tissue Expander
The flagship products of Establishment Labs, Motiva Implants, represent a line of silicone gel-filled breast implants renowned for their superior design and safety profiles. These implants are engineered to meet the varied aesthetic and reconstructive needs of patients, encapsulating the company's commitment to innovation and patient satisfaction.
Motiva Ergonomix and Motiva Ergonomix2 are specifically designed to mimic the natural movement of breast tissue, offering a gravity-sensitive option within the silicone gel-filled breast implants category. These products demonstrate Establishment Labs’ prowess in creating implants that provide a natural look and feel, thereby enhancing patient outcomes and comfort.
The Motiva Flora Tissue Expander is a surgical device intended for use in breast reconstruction procedures. It enables the gradual expansion of breast tissue, facilitating the subsequent insertion of a breast implant. This product underscores Establishment Labs’ contribution to the field of reconstructive surgery, offering innovative solutions that support patient recovery and aesthetic reconstruction.
